|
|
Next Article 
Blood, Vol. 90 No. 6 (September 15), 1997:
pp. 2121-2126
EDITORIAL
Intensifying Induction Therapy in Acute Myeloid Leukemia: Has a New Standard of Care Emerged?
By
Jacob M. Rowe and
Martin S. Tallman
From the University of Rochester Medical Center, Rochester, NY; Rambam Medical Center, Technion, Haifa, Israel; and the Northwestern University Medical Center, Chicago, IL.
 |
ARTICLE |
INDUCTION THERAPY for acute myeloid leukemia (AML) has been fairly standardized over the past two decades, with major controversies addressing the optimal postremission therapy. Nevertheless, whereas the most common induction therapy for AML consists of 3 days of an anthracycline, usually daunorubicin, and 7 days of cytarabine (3 + 7), many trials have been conducted in an attempt to improve this standard by introducing a more intensive combination with potential to improve the complete remission rate, remission duration, or the number of patients cured.
Modern therapy with AML begun some 30 years ago with the introduction of cytosine arabinoside1,2 and daunorubicin.3 With either of these single agents, 30% to 40% of adults attained a complete response and a small proportion of these patients were long-term survivors. Significant further improvement occurred with the introduction of combination chemotherapy for AML induction. For much of the past two decades, induction therapy has consisted of daunorubicin, cytarabine, and 6-thioguanine (DAT).4-8 Most investigators now have eliminated 6-thioguanine from the standard induction regimen because its inclusion was not shown to improve overall results.9,10 Although there is no single established induction regimen, the most widely used combination for treatment of newly diagnosed AML has been daunorubicin (the first available anthracycline3 ) at a dose of 45 mg/m2 intravenously for 3 days and cytarabine at a dose of 100 mg/m2 intravenously by continuous infusion for 7 days.11 This is the standard against which most new regimens are tested. With this regimen, between 50% and 75% of adult patients with AML achieve complete remission,12-14 but 25% to 40% of patients require more than one course of induction to achieve complete remission.14-17 A randomized study by the Cancer and Leukemia Group B (CALGB) established that reducing the dose of daunorubicin to 30 mg/m2 resulted in a lower response rate, particularly in adults less than 60 years of age.18
Increasing the intensity of induction has generated considerable recent interest and such a strategy may be effective in at least two ways. First, because achieving complete remission is considered a sine qua non for prolonged disease-free survival, it is likely that any combination that alters the complete remission rate will affect the long-term outcome. Second, intensified induction therapy may affect the long-term survival without an apparent effect on the initial response rate. However, reports of improved disease-free survival attributable to intensified induction therapy need to be cautiously interpreted. Such benefit may be impossible to determine without regard to the choice of postremission therapy, much like the difficulty in evaluating the results of consolidation therapy without considering the type of induction. Finally, any strategy to intensify induction may lead to more profound myelosuppression and the potential for toxicity needs to be carefully considered. Such an approach may be associated with more severe treatment-related morbidity and mortality or, alternatively, toxicity may be less if fewer patients require more than one course of induction therapy.
Several studies have explored the benefits of amsacrine,19,20 aclarubicin,21,22 mitoxantrone,15 and idarubicin.23-27 Several well-conducted randomized trials showed that idarubicin,24-26 aclarubicin,22 and amsacrine20 may be superior to daunorubicin in younger adults. Furthermore, a randomized study suggested that mitoxantrone15 is at least as effective as daunorubicin. However, these agents have been compared with daunorubicin at a dose of 45 mg/m2. Notwithstanding theoretical advantages to the use of idarubicin,28-31 it is not clear that any observed improvement represents an inherent biologic advantage of a particular drug rather than biologic dose equivalence. There are no data to suggest that a higher dose of daunorubicin is more effective, because a prospective comparison of daunorubicin 45 mg/m2 versus 60 mg/m2 or higher has not been conducted. However, studies by the Southwest Oncology Group (SWOG) have reported a substantially better complete response rate with daunorubicin at a dose of 70 mg/m2 32 compared with 45 mg/m2.33 Although this was not a randomized comparison, these were sequential studies by the same cooperative group in which only the dose of daunorubicin varied. Randomized data comparing idarubicin with daunorubicin may illustrate this point. Whereas three randomized studies demonstrated an unequivocal or a trend towards improved results for idarubicin when compared with daunorubicin at 45 mg/m2, sequential studies by the Eastern Cooperative Oncology Group (ECOG) have shown that the complete response rate, achieved in more than 800 patients, with idarubicin at a dose of 12 mg/m2 was identical to the historical control in a similar number of patients that used 60 mg/m2 of daunorubicin.34,35
Comparisons of dose intensity in AML are complicated by many factors such as patient age, antecedent myelodysplasia, supportive care, and patient selection. For example, a complete response rate of 81% achieved with 90 mg/m2 of daunorubicin has been reported.36 However, this study is not easily compared with other studies of AML in adults because the median age was only 31 years. Similarly, it is difficult to interpret the pilot study in which a higher dose of mitoxantrone (80 mg/m2 as a single bolus infusion) was tested in 20 patients yielding an 85% complete response rate.37 Although escalating the dose of induction appears beneficial in younger adults, data in older adults are conflicting. Some studies suggest that the increased regimen-related toxicity outweighs the clinical benefit.22,38 However, this has not been confirmed by others.11,39-41 Furthermore, some investigators have recommended against any dose attenuation of induction therapy.42,43
Modifications in the dose and duration of cytarabine have also been addressed. Increasing the duration of cytarabine, from 7 to 10 days, has yielded, at best, modest improvement, particularly in younger adults.9,44 These CALGB trials showed that increasing the dose of cytarabine from 100 to 200 mg/m2/d did not lead to a significant improvement, and a randomized study evaluating a dose of 500 mg/m2 yielded similar results.45 However, administering cytarabine by continuous infusion was shown to be more effective than by bolus injection.11 Several prospective studies have compared induction regimens that modify both the dose of anthracycline and cytarabine.46,47 Therefore, meaningful interpretation is difficult. A regimen frequently used in Europe, consisting of mitoxantrone, etoposide, and cytarabine,48 has not been shown to be superior to standard induction therapy.
Cytarabine has also been used in induction in high doses (HDAC) since the initial report of its utility in refactory AML.49 Response rates as high as 90% have been reported with HDAC at doses of 1.5 to 3.0 g/m2 every 12 hours for 3 to 6 days.50-53 Most of these studies used HDAC either as a single agent52 or as a combination with either daunorubicin,53 amsacrine,51 or asparaginase.50 Toxicity was considereable; relatively small cohorts of patients were treated and the response rates were compared with historical controls. Only two randomized studies have directly compared HDAC with standard induction therapy while using the same postremission therapy in both arms.33,54 In contrast to earlier uncontrolled trials, these two studies reported that the complete response rate was not higher with HDAC than with standard induction therapy and was associated with increased toxicity. However, both studies noted a significantly longer disease-free survival for those patients receiving HDAC in induction.
The concept that intensifying induction therapy may not improve the initial response rate but may affect the long-term outcome has also been shown in a prospective randomized study when etoposide was added to standard induction therapy.55,56 Although showing that dose intensity of induction therapy may affect the duration of remission in AML, it is not clear that the increased toxicity through more profound myelosuppression is advantageous given the possibility that a similar intensification might be safely added during postremission therapy.
An alternative approach, namely adding HDAC directly after the standard 3 + 7 induction, ie, on days 8 through 10, was recently reported.57 The principle supporting this strategy involves both an intensification of current existing regimen as well as the potential benefit of timed sequential chemotherapy.58-62 Although a high response rate was reported (89%), this result was compared with historical controls. Furthermore, this was a limited-institution study and the literature describing AML therapy is replete with very high response rates initally reported from such limited studies, which could not be reproduced in large cooperative group trials. For example, the initial superior response to cytarabine and amsacrine reported in induction63 or consolidation51 was not confirmed in large cooperative group settings.34,64 Nevertheless, this approach is intriguing and two cooperative groups are currently conducting phase II studies investigating this strategy.
Administering intensive chemotherapy immediately after initial induction may lead to an improved long-term outcome. There are data that suggest that, after initial intensive induction therapy, residual leukemic cells may be recruited into the cell cycle, making them more susceptible to cell cycle-specific agents such as cytarabine.60,61,65,66 Several phase II studies have suggested that a number of patients who receive one or two courses of chemotherapy at time of maximal recruitment (6 to 10 days after initial therapy) could have a prolonged disease-free survival without further therapy.50,58,59,67 Whether these results are due to the biologic recruitment of cell cycle-specific agents or whether this represents the most effective consolidation at the optimal period of minimal residual disease is unknown. However, administering a repeat course of induction shortly after completion of the first course has been tested and its toxicity is known, because approximately 25% to 40% of adult patients with AML require a second course of induction at day 11 through 14 after the start of induction chemotherapy.14-17 Therefore, an alternative method of intensification may be to administer a second course of induction therapy on days 10 through 14 to all patients, including those who achieve marrow hypoplasia. Such a concept appears effective in children,68 but has never been tested in adults, although several attempts at administering a repeat or second induction at intervals of 21 days have been successfully reported.69
Hematopoietic growth factors have been shown to shorten the period of neutropenia after induction therapy for AML,70,71 and several studies have reported reduced morbidity.17,72-74 There are also promising preclinical data exploring the use of thrombopoietin to shorten the period of thrombocytopenia.75 The best clinical use of these cytokines has not yet been described. Despite the potential for reducing morbidity after myelosuppressive therapy, there are no data that more intensive therapy can be safely delivered with cytokine support.
The current standard for inducing complete remission in previously untreated adults with de novo AML remains an anthracycline and cytarabine. Although there are promising areas for clinical investigation, at the present time a new standard of care for induction therapy has not yet emerged. Although there appear to be better agents than 45 mg/m2 of daunorubicin, the optimal anthracycline and dose has yet to be described. Prospective studies should determine whether escalating the doses of anthracyclines will yield improved response rates. Similarly, the addition of intensive therapy to the current standard regimen, such as high-dose cytarabine or etoposide, although clearly affecting the long-term remission duration, has not been shown to significantly affect the long-term outcome by comparison with known published postremission therapies.14,16 Some of the potential future strategies are summarized in Table 1. With the current high response to induction therapy it is crucial to have prospective randomized studies to determine whether any of these maneuvers are significantly better than standard induction therapy followed by optimal postremission therapy. Single-arm phase II trials should be limited to carefully designed studies describing efficacy and toxicity in regimens involving usually not more than a single change from standard therapy. Cooperative groups have a major role in this regard and should help to define any modifications to current therapy. Unfortunately, at present, only a minority of adults with AML enter cooperative group trials.76 Improved accrual must be encouraged, allowing for more rapid generation of data. It is also important to design studies that can be completed within a reasonable time frame, thus stimulating patient and physician interest and leading to further accrual. With these efforts it is hoped that the next decade may clearly identify a better strategy for induction therapy in AML.
| |
FOOTNOTES |
Submitted May 13, 1997;
accepted June 27, 1997.
Address reprint requests to Jacob M. Rowe, MD, University of Rochester Medical Center, 601 Elmwood Ave, Rochester, NY 14642.
The publication costs of this article were defrayed in part by page
charge payment. This article must therefore be hearly marked
``advertisment'' in accordance with 18 U.S.C. section 1734 solely to
indicate this fact.
| |
ACKNOWLEDGMENT |
The authors thank Peter A. Cassileth, MD, for reviewing the manuscript and Federick R. Appelbaum, MD, for providing SWOG data.
| |
REFERENCES |
1.
Freireich EJ:
Arabinosyl cytosine: A 20 year update.
J Clin Oncol
5:523,
1987[Free Full Text]
2. Coltman CA, Freireich EJ, Pendleton O, Bickers JN, Bodey GP, Hewlett JS, McCredie KB: Adult acute leukemia studies using cytarabine: Early Southwest Oncology Group trials. Med Pediatr Oncol 10:173, 1982 (suppl 1)
3. Weil M, Glidewell OJ, Jacquillat C, Levy R, Serpick AA, Wiernik PH, Cuttner J, Hoogstraten B, Wasserman L, Ellison RR, Gailani S, Brunner K, Silver RT, Rege VB, Cooper MR, Lowenstein L, Nissen NI, Haurani F, Blom J, Boiron M, Bernard J, Holland JF :Daunorubicin in the therapy of acute granulocytic leukemia. Cancer Res 33:921, 1973
4.
Rees JKH,
Sandler RM,
Challener J,
Hayhoe FGJ:
Treatment of acute myeloid leukemia with triple cytotoxic regimen: DAT.
Br J Cancer
36:770,
1977[Medline]
[Order article via Infotrieve]
5.
Gale RP,
Cline MJ:
High remission rate in acute myelocytic leukemia.
Cancer
1:497,
1977
6.
Mandelli F,
De Lipsis E,
Gregnani F,
Martelli M,
Liso V,
Amadori S:
Daunomycin, cytosine arabinoside and 6-thioguanine (DAT) vs vincristine, cytosine arabinoside, and 6-thioguanine (VAT) in the induction treatment of acute nonlymphocyte leukemia: A randomized collaborative study.
Med Pediatr Oncol
4:231,
1978[Medline]
[Order article via Infotrieve]
7. Arlin Z, Gee T, Fried J, Clarkson B: Rapid induction of remission in acute nonlymphocytic leukemia. Proc Am Assoc Cancer Res 20:112a, 1979 (abstr)
8.
Wiernik PH,
Glidewell OJ,
Hoagland HC,
Brunner KW,
Spurr CL,
Cuttner J,
Silver RT,
Carey RW,
DelDuca V,
Kung FH,
Holland:
A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemia.
Med Pediatr Oncol
6:261,
1979[Medline]
[Order article via Infotrieve]
9.
Preisler HD,
Davis RB,
Kirshner J,
Dupre E,
Richards F,
Hoagland HC,
Kopel S,
Levy RN,
Carey R,
Schulman P,
Gottlieb AJ,
McIntyre OR:
Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: A Cancer and Leukemia Group B study.
Blood
69:1441,
1987[Abstract/Free Full Text]
10.
Omura GA,
Vogler WR,
Lesante J,
Silberman H,
Knospe W,
Gordan D,
Jarrel R:
Treatment for acute myelogenous leukemia: Influence of three induction regimens and maintenance with chemotherapy or BCG immunotherapy.
Cancer
49:1530,
1982[Medline]
[Order article via Infotrieve]
11.
Rai KR,
Holland JF,
Glidewell O,
Weinberg V,
Brunner K,
Obrecht JP,
Preisler HD,
Nawabi JW,
Prager D,
Carey RW,
Cooper MR,
Haurani F,
Hutchinson JL,
Silver RT,
Falkson G,
Wiernik P,
Hoagland HC,
Bloomfield CD,
James GW,
Gottlieb A,
Ramanan SV,
Blomb J,
Nissen N,
Bank A,
Ellison RR,
Kung F,
Henry P,
McIntyre OR,
Kaan SK:
Treatment of acute myelocytic leukemia: A study of the Cancer and Leukemia Group B.
Blood
58:1203,
1981[Free Full Text]
12.
Preisler HD,
Anderson K,
Rai K,
Cuttner J,
Yates J,
DuPre E,
Holland JF:
The frequency of long-term remission in patients with acute myelogenous leukaemia treated with conventional maintenance chemotherapy: A study of 760 patients with a minimal follow-up time of 6 years.
Br J Haematol
71:198,
1989
13.
Bandini G,
Zuffa E,
Rosti G,
Battista R,
D'Emilio E,
Leoni F,
Ciolli S,
Barbui T,
Bassan R,
Todeschini G,
Perona G,
Scapoli G,
Mangoni L,
Morra E,
DiPeisco U,
Visani G,
Tura S:
Long-term outcome of adults with acute myelogenous leukemia: Results of a prospective randomized study of chemotherapy with a minimal follow-up of 7 years.
Br J Haematol
77:486,
1991[Medline]
[Order article via Infotrieve]
14.
Stone RM,
Mayer RJ:
Treatment of the newly diagnosed adult with de novo acute myeloid leukemia.
Hematol Oncol Clin North Am
7:47,
1993[Medline]
[Order article via Infotrieve]
15.
Arlin Z,
Case DC,
Moore J,
Wiernik P,
Feldman E,
Saletan S,
Desei P,
Sai L,
Cartwright K:
Randomized multi-center trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL).
Leukemia
4:177,
1990[Medline]
[Order article via Infotrieve]
16.
Mayer RJ,
Davis RB,
Schiffer CA,
Berk DT,
Powell BL,
Schulman P,
Omura GA,
Moore JO,
Mcintyre OR,
Frei E,
for the Cancer and Leukemia Group B:
Intensive postremission chemotherapy in adults with acute myeloid leukemia.
N Engl J Med
331:896,
1994[Abstract/Free Full Text]
17.
Rowe JM,
Andersen J,
Mazza JJ,
Paietta E,
Bennett JM,
Hayes A,
Oette D,
Wiernik PH:
Phase III randomized-placebo controlled study on granulocyte-macrophage colony stimulating factor (G-MCSF ) in adult patients (55-70 years) of acute myelogenous leukemia (AML). A study of the Eastern Cooperative Oncology Group (ECOG).
Blood
86:257,
1995
18.
Yates J,
Glidewell OJ,
Wiernik P,
Cooper MR,
Steinberg D,
Dosik H,
Levy R,
Hoaglend AC,
Henry P,
Gottlieb A,
Cornell C,
Berenberg J,
Hutchison JL,
Raich P,
Nissen N,
Ellison RR,
Frelick R,
James GW,
Falkson G,
Silver RT,
Haurani F,
Green M,
Henderson E,
Leon L,
Holland JF:
Cytosine arabinoside with daunorubicin or adriamycin therapy with acute myelocytic leukemia: A CALGB study.
Blood
60:454,
1982[Abstract/Free Full Text]
19.
Legha SS,
Keating MJ,
McCredie KB,
Bodey GP,
Freireich EJ:
Evaluation of AMSA in previously treated patients with acute leukemia: Results of therapy in 109 adults.
Blood
60:484,
1982[Abstract/Free Full Text]
20.
Berman E,
Arlin ZA,
Gaynor J,
Miller W,
Gee T,
Kempin SJ,
Mertelsmann R,
Andraeft M,
Reich L,
Nahmias N,
Clarkson B:
Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: Results of the L-16M protocol.
Leukemia
3:115,
1989[Medline]
[Order article via Infotrieve]
21.
Warrell RP,
Arlin ZA,
Kempin SJ,
Young CW:
Phase I-II evaluation of a new anthracycline antibiotic, aclacinomycin A, in adults with refractory leukemia.
Cancer Treat Rep
66:1619,
1982[Medline]
[Order article via Infotrieve]
22.
Hansen OP,
Pedersen-Bjergaard J,
Ellegaard G,
Brincker H,
Doesen AM,
Christen BE,
Drivsholm A,
Hippe E,
Jans H,
Jensen KB,
Killmann SD,
Jensen MK,
Karle H,
Laursen B,
Nielsen JB,
Nissen NI,
Thorling K:
Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients of acute myeloid leukemia: A Danish National Phase III Trial. For the Danish Society of Hematology Study Group on AML.
Leukemia
5:510,
1991[Medline]
[Order article via Infotrieve]
23.
Berman E,
Raymond Z,
Daghestani A,
Arlin ZA,
Gee TS,
Kempin S,
Hancock C,
Williams L,
Stevens YW,
Clarkson BD,
Young C:
4-Demethoxydaunorubicin (idarubicin) in combination with 1- -D-Arabinofuranosylytosine in a treatment of relapsed or refractory acute leukemia.
Cancer Res
49:477,
1989[Abstract/Free Full Text]
24.
Berman E,
Heller G,
Santorsa J,
McKenzie S,
Gee T,
Tempin F,
Gulati S,
Andreess M,
Kolitz J,
Gabrilove J,
Reich L,
Mayer K,
Keefe D,
Trainor K,
Schluger A,
Penenberg D,
Raymond V,
O'Reilly R,
Jhanwar S,
Young C,
Clarkson B:
Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia.
Blood
77:1666,
1991[Abstract/Free Full Text]
25.
Vogler WR,
Velez-Garcia E,
Weiner RS,
Flaum MA,
Bartolucci AA,
Omura GA,
Gerber MC,
Banks PL:
A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group.
J Clin Oncol
10:1103,
1992[Abstract]
26.
Wiernik PH,
Banks PLC,
Case DC,
Arlin ZA,
Periman PO,
Todd MB,
Ritch TS,
Enck R,
Weitberg AB:
Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.
Blood
79:313,
1992[Abstract/Free Full Text]
27.
Mandelli F,
Petti MC,
Ardia A,
Di Pietro N,
Di Raimondo F,
Ganzina F,
Falconi E,
Geraci E,
Ladogana S,
Latagliata R,
Malleo C,
Nobile F,
Petti N,
Rotoli B,
Specchia G,
Tabilio A,
Luigi R:
A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukemia. A multicentric study from the Italian Co-operative Group GIMEMA.
Eur J Cancer
27:750,
1991
28.
Berman E,
McBride N:
Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells.
Blood
79:3267,
1992[Abstract/Free Full Text]
29.
Muller MR,
Lennartz K,
Boogen C,
Nowrousian MR,
Rajewsky MF,
Seeber S:
Cytotoxicity of adriamycin, idarubicin, and vincristine in acute myeloid leukemia: Chemosensitization by verapamil in relation to P-glycoprotein expression.
Ann Hematol
65:206,
1992[Medline]
[Order article via Infotrieve]
30.
Robert J,
Rigal-Huguet F,
Hurteloup P:
Comparitive pharamacokinetic study of idarubicin and daunorubicin in leukemia patients.
Hematol Oncol
10:111,
1992[Medline]
[Order article via Infotrieve]
31.
Petrini M,
Mattii L,
Valentini P,
Sabbatini AR,
Grassi B,
Grandi M:
Idarubicin is active on MDR cells: Evaluation of DNA synthesis inhibition on P388 cell lines.
Ann Hematol
67:227,
1993[Medline]
[Order article via Infotrieve]
32.
Hewlett J,
Kopecky KJ,
Head D,
Eyre HJ,
Elias L,
Kingsburg L,
Balcerzak ST,
Dabich L,
Hynes H,
Bickers JN,
Appelbaum FR:
A prospective evaluation of the roles of allogeneic marrow transplantation and low-dose monthly maintenance chemotherapy in a treatment for adult acute myelogenous leukemia (AML): A Southwest Oncology Group study.
Leukemia
9:562,
1995[Medline]
[Order article via Infotrieve]
33.
Weick JK,
Kopecky TJ,
Appelbaum FR,
Head DR,
Kingsbury LL,
Balcerzak SP,
Ickers JN,
Hynes HE,
Welborn JL,
Simon SR,
Grever M:
A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previosly untreated acute myeloid leukemia: A Southwest Oncology Group study.
Blood
88:2841,
1996[Abstract/Free Full Text]
34.
Cassileth PA,
Lynch E,
Hines JD,
Oken MM,
Mazza JJ,
Bennett JM,
McGlave PB,
Edelstein M,
Harrington DP,
O'Connell MJ:
Varying intensitiy of postremission therapy in acute myeloid leukemia.
Blood
79:1924,
1992[Abstract/Free Full Text]
35. Cassileth P, Harrington D, Paietta E, Lazarus H, Appelbaum F, Blume K, Bennett J, Hurd D, Willman C, Slovak M, Wiernik P: Comparison of autologous bone marrow transplantation(AutoBMT) with high-dose cytarabine (HDAC) in adult acute myeloid leukemia (AML) in first remission (CR1): An ECOG Intergroup study. Proc Am Soc Clin Oncol 16:89a, 1997 (abstr)
36.
Appelbaum FR,
Dahlberg S,
Thomas ED:
Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison.
Ann Intern Med
101:581,
1984
37.
Feldman EJ,
Alberts TS,
Arlin Z,
Ahmed T,
Mittelman A,
Baskind P,
Peng YM,
Baer M,
Plezia P:
Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
J Clin Oncol
10:2002,
1993
38.
Kahn SB,
Begg CB,
Maza JJ,
Bennett JM,
Bonner H,
Glick JH:
Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in a treatment for acute nonlymphocytic leukemia in the elderly.
J Clin Oncol
2:865,
1984[Abstract]
39.
Tilly H,
Castaigne S,
Bordessoule D,
Casassus P,
Le Prise PY,
Tertian G,
Desablens BB,
Henry-Amar M,
Degos L:
Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly.
J Clin Oncol
8:272,
1990[Abstract]
40. Rees JKH: Chemotherapy of acute myeloid leukemia in UK: Past, present and future. Bone Marrow Transplant 4:110, 1989 (suppl 1)
41. Dutcher JP, Strauman JJ, Wiernik PH: Treatment of acute nonlymphocytic leukemia in patients older than 60 years of age. Blood 64:163a, 1984 (abstr, supp 1)
42. Büchner TH, Hiddemann W, Maschmeyer G, Ludwig G, Aul C, Lathan B, Lengffelder B, Sauerland MC, Heinecke A: AML in patients of 60+ years: Full versus reduced dose induction. Randomized study of the AMLCG. Blood 80:209a, 1992 (abstr, suppl 1)
43.
Sebban C,
Archimbaud E,
Coiffier B,
Guyotat D,
Treille-Ritouet D,
Maupas J,
Fiere D:
Treatment of acute myeloid leukemia in elderly patients. A retrospective study.
Cancer
61:227,
1988[Medline]
[Order article via Infotrieve]
44.
Dillman RO,
Davis RB,
Green MR,
Weiss RB,
Gottlieb AJ,
Caplan S,
Kopel S,
Preisler H,
McIntyre OR,
Schiffer C:
A comparative study of two different doses of cytarabine for acute myeloid leukemia: A phase III trial of Cancer and Leukemia Group B.
Blood
78:2520,
1991[Abstract/Free Full Text]
45.
Schiller G,
Gajewski J,
Mimers S,
Territo M,
Ho W,
Loc M,
Champlin R:
A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukemia.
Br J Haemetol
81:170,
1992
46.
Rees JK,
Gray G,
Wheatley K:
Dose intensification in acute myeloid leukemia: Great effectiveness at lower cost. Principal report of a Medical Research Council's AML 9 study.
Br J Haematol
94:89,
1996[Medline]
[Order article via Infotrieve]
47.
Feldman E,
Seiter K,
Damon L,
Linker C,
Rugo H,
Ries C,
Case DC,
Beer M,
Ahmed P:
The randomized trial of high-vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia.
Leukemia
11:485,
1997[Medline]
[Order article via Infotrieve]
48.
Archimbaud E,
Fenaux P,
Reiffers J,
Cordonnier C,
Leblond V,
Travade P,
Troussard X,
Tilly H,
Auzann Cau G,
Marie JP:
Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide and cytarabine for refractory acute myelogenous leukemia.
Leukemia
7:372,
1993[Medline]
[Order article via Infotrieve]
49.
Rudnick S,
Cadman E,
Capizzi R:
High-dose cytosine arabinoside (HDARAC) in refractory acute leukemia.
Cancer
44:1189,
1979[Medline]
[Order article via Infotrieve]
50.
Capizzi RL,
Poole M,
Coopler MR,
Richards F,
Stuart JJ,
Jackson DV,
White DR,
Spurr CL,
Hopkins JO,
Muss HB:
Treatment of poor risk acute leukemia with sequential high dose ara-c and asparaginase.
Blood
63:694,
1984[Abstract/Free Full Text]
51.
Hines JD,
Mazza JJ,
Oken MM,
Bennett JM,
Adelstein DJ,
Keller A,
O'Connell MJ:
High-dose cytosine arabinoside and m-AMSA induction and consolidation in patients with de novo acute non-lymphocytic leukemia: A phase I pilot study of the Eastern Cooperative Oncology Group.
Semin Oncol
12:117,
1985[Medline]
[Order article via Infotrieve]
52.
Curtis JE,
Messner HA,
Minden MD,
Minkin S,
McCullocogh EA:
High dose cytosine arabinoside (ara-c) in the treatment of acute myelogenous leukemia: Contributions to outcome of clinical and laboratory attriibutes.
J Clin Oncol
5:532,
1987[Abstract/Free Full Text]
53.
Phillips GL,
Reece DE,
Shepherd JD,
Barnett MJ,
Brown RA,
Frei-Lahr DA,
Klingemann HG,
Bolwell BJ,
Spinelli JJ,
Herzig RH,
Herzig GP:
High-dose cytarabine and daunorubicin induction and postremission chemothreapy for the treatment of acute myelogenous leukemia in adults.
Blood
77:1429,
1991[Abstract/Free Full Text]
54.
Bishop JS,
Matthews JP,
Young GA,
Szer J,
Gillett A,
Joshua D,
Bradstock K,
Enno A,
Wolf MM,
Fox R,
Cobcroft R,
Herrmann R,
Van der Weyden M,
Lowenthal RM,
Page F,
Garson M,
Juneja S:
A randomized trial of high-dose cytarabine in induction in acute myeloid leukemia.
Blood
87:1710,
1996[Abstract/Free Full Text]
55.
Bishop JS,
Lowenthel R M,
Joshua D,
Mattthews JT,
Todd D,
Cobcroft R,
Whiteside MG,
Kronenberg H,
Ma D,
Dodds A,
Herrmann R,
Szer J,
Wolf MM,
Young G,
Australian Study Group:
Etoposide in acute non-lymphocytic leukemia.
Blood
75:27,
1990[Abstract/Free Full Text]
56.
Bishop JS:
Intensified therapy for acute myeloid leukemia.
N Engl J Med
331:941,
1994[Free Full Text]
57.
Mitus AJ,
Miller KB,
Schenkein DP,
Ryan HF,
Parsons SK,
Wheeler C,
Antin JH:
Improved survival for patients with an acute myelogenous leukemia.
J Clin Oncol
13:560,
1995[Abstract/Free Full Text]
58.
Vaughan WP,
Carp JE,
Burke PJ:
Long chemotherapy-free remission after single-cycle timed-sequential chemotherapy for acute myelocytic leukemia.
Cancer
45:859,
1980[Medline]
[Order article via Infotrieve]
59.
Vaughan WP,
Carp JE,
Burke PJ:
Two-cycle timed-sequential chemotherapy for adult acute nonlymphocytic leukemia.
Blood
5:975,
1984
60.
Karp JE,
Burke PJ:
Enhancement of drug pshychotoxicity by recruitment of leukemic myeloblasts with humoral stimulation.
Cancer Res
36:3600,
1976[Abstract/Free Full Text]
61.
Karp JE,
Donehower RC,
Dole G,
Burke PJ:
Correlation of drug-perturbed marrow cell growth kinetics and intracellular of 1--D-Furanosylcytosine metabolism with clinical response in adult acute myelogenous leukemia.
Blood
69:1134,
1987[Abstract/Free Full Text]
62.
Murtens ACM,
Van Bekkum DW,
Hagenbeek A:
The BN acute myelocytic leukemia (BNML): A rat model for studying human myelocytic acute leukemia.
Leukemia
4:244,
1990
63.
Arlin ZA,
Ahmed T,
Mittelman A,
Feldman E,
Mehta R,
Weinstein P,
Rieber E,
Sullivan P,
Baskind P:
A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia.
J Clin Oncol
5:371,
1987[Abstract]
64. Karanes C, Kopeckey KJ, Durie BGM, Grever MR: Increased risk of early death with high-dose Ara-C and m-AMSA compared to high-dose Ara-C alone or high-dose Ara-C and mitoxantrone in high risk nonlymphosytic leukemia. Proc Am Soc Clin Oncol 8:201a, 1989 (abstr)
65.
Lampkin B,
Nagao T,
Mauer A:
Synchronization and recruitment in acute leukemia.
J Clin Invest
50:2204,
1971
66.
Lampkin B,
McWilliams N,
Mauer A,
Flessa H,
Hako D,
Fisher V:
Manipulation of the mitotic cycle in a treatment myelogenous leukemia.
Br J Haematol
32:29,
1976[Medline]
[Order article via Infotrieve]
67.
Burke PJ,
Karp JE,
Geller RB,
Vaughan WP:
Cures of leukemia with aggressive postremission treatment: An update of timed sequential therapy (Ac-D-Ac).
Leukemia
3:692,
1989[Medline]
[Order article via Infotrieve]
68.
Woods WG,
Kobrinsky N,
Buckley JD,
Lee JW,
Sanders J,
Neudorf S,
Gold S,
Barnard DR,
DeSwarte J,
Dusenbery K,
Kalousek D,
Arthur DC,
Lange BJ:
Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: A report from the Childrens Cancer Group.
Blood
67:4979,
1996
69. Büchner T, Hiddemann W, Wörmann B, Löffler H, Maschmeyer, G, Hossfeld D, Ludwig WD, Nowrousian M, Aul C, Schaefer W, Sauerland C, Heinecke A: Long term effects of prolonged maintenance and of very early intensification chemotherapy in AML: Data from AMLCG. Leukemia 6:68, 1992 (suppl 2)
70.
Schiffer CA:
Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia.
Blood
88:3675,
1996[Abstract/Free Full Text]
71.
Rowe JM,
Liesveld JL:
Hematopoietic growth factors in acute leukemia.
Leukemia
11:328,
1997[Medline]
[Order article via Infotrieve]
72.
Ohno R,
Tomonaga M,
Kobayashi T Kanamaru A,
Shrakawa S,
Masaoka T,
Omine M,
Oh H,
Nomura T,
Sakai Y,
Hirano M,
Yokomaku S,
Nakayma S,
Yoshida Y,
Miura AD,
Morishima Y,
Dohy H,
Niho Y,
Hamajima N,
Takaku F:
Effect of granulocyte-colony stimulating factor after intentive induction therapy in relapsed or refractory acute leukemia.
N Engl J Med
323:871,
1990[Abstract]
73.
Büchner T,
Hiddemann W,
Koenigsmann M,
Zühlsdorf M,
Wörmann B,
Boeckmann A,
Freire EA,
Innig G,
Maschmeyer G,
Ludwig WD,
Sauerland MC,
Heineck A,
Schulz G:
Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse.
Blood
78:1190,
1991[Abstract/Free Full Text]
74. Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin J, Papa G, Noens L, Ho J, O'Brien C, Matcham J, Barge A: Results of a randomized, double-blind placebo controlled phase III study of filgrastim in remission induction and early consolidation therapy for adults with de-novo acute myeloid leukemia. Blood 86:267a, 1995 (abstr, suppl 1)
75.
Kaushansky K,
Lok S,
Holly RD,
Broudy VC,
Lin N,
Bailey MC,
Forstron JW,
Buddle MM,
Oort PJ,
Hagen FS:
Promotion of megakaryocyte progenitor expansion and differentiation by the c-mpl ligand thrombopoietin.
Nature
369:568,
1994[Medline]
[Order article via Infotrieve]
76.
Benson AB,
Pregler JP,
Bean JA,
Rademaker AW,
Eshler B,
Anderson K:
Oncologists' reluctance to accrue patients on to clinical trials: Illinois Cancer Center Study.
J Clin Oncol
9:2067,
1991[Abstract/Free Full Text]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. Blaise, N. Vey, C. Faucher, and M. Mohty
Current status of reduced intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia
Haematologica,
April 1, 2007;
92(4):
533 - 541.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Hegenbart, D. Niederwieser, B. M. Sandmaier, M. B. Maris, J. A. Shizuru, H. Greinix, C. Cordonnier, B. Rio, A. Gratwohl, T. Lange, et al.
Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors
J. Clin. Oncol.,
January 20, 2006;
24(3):
444 - 453.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Tallman, D. G. Gilliland, and J. M. Rowe
Drug therapy for acute myeloid leukemia
Blood,
August 15, 2005;
106(4):
1154 - 1163.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Mesa, D. Loegering, H. L. Powell, K. Flatten, S. J. H. Arlander, N. T. Dai, M. P. Heldebrant, B. T. Vroman, B. D. Smith, J. E. Karp, et al.
Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine
Blood,
July 1, 2005;
106(1):
318 - 327.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Stein, M. R. O'Donnell, M. L. Slovak, D. S. Snyder, A. P. Nademanee, P. Parker, A. Molina, G. Somlo, H. C. Fung, A. Krishnan, et al.
Interleukin-2 After Autologous Stem-Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete Remission
J. Clin. Oncol.,
February 15, 2003;
21(4):
615 - 623.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. R. Appelbaum, J. M. Rowe, J. Radich, and J. E. Dick
Acute Myeloid Leukemia
Hematology,
January 1, 2001;
2001(1):
62 - 86.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. K. Parsons, S. Gelber, B. F. Cole, Y. Ravindranath, A. Ogden, A. M. Yeager, M. Chang, J. Shuster, H. J. Weinstein, and R. D. Gelber
Quality-Adjusted Survival After Treatment for Acute Myeloid Leukemia in Childhood: A Q-TWiST Analysis of the Pediatric Oncology Group Study 8821
J. Clin. Oncol.,
July 1, 1999;
17(7):
2144 - 2144.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
Article
References
Article